Autoimmune Encephalitis medical therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
|
Autoimmune Encephalitis Microchapters |
|
Differentiating Autoimmune Encephalitis from Other Conditions |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune Encephalitis On the Web |
Overview
Autoimmune encephalitis requires early disease-directed treatment when the diagnosis is sufficiently supported. Immunotherapy selection depends on severity, antibody subtype, associated neoplasm, and response. Investigate infection and other mimics urgently; empirical intravenous acyclovir is indicated while herpes simplex encephalitis remains possible. Do not await antibody results once evidence supports treatment and infection has been reasonably excluded.[1]
Medical Therapy
First-Line Treatment in Adults
Autoimmune encephalitis is treated with corticosteroids, intravenous immunoglobulin (IVIG), and/or plasma exchange. Canadian consensus recommends combined treatment for severe disease; corticosteroid monotherapy may be appropriate in selected mild or moderate cases.[2]
| Treatment | Common adult regimen |
|---|---|
| Methylprednisolone | 1 g intravenously daily for 5 days |
| Intravenous immunoglobulin | Total 2 g/kg divided over 2–5 days |
| Plasma exchange | First-line procedural option; see therapeutic plasma exchange |
Regimens require specialist supervision. A corticosteroid taper may follow acute treatment; Canadian guidance describes oral prednisone 0.5–1 mg/kg/day tapered over approximately 4–12 weeks, individualized to response and toxicity.[2]
Treatment Escalation
Autoimmune encephalitis response should be assessed clinically and objectively. Canadian guidance considers failure after 5–10 days in severe disease or 2–4 weeks in milder disease.[2] The 2026 United Kingdom guideline uses a general 2–4-week reassessment window. Deterioration warrants earlier specialist review.[1]
Autoimmune encephalitis refractory to first-line treatment may require:
- Rituximab: Common adult induction regimens are 1 g intravenously twice, two weeks apart, or 375 mg/m2 weekly for four doses.
- Cyclophosphamide: Common adult regimens use 600–1,000 mg/m2 intravenously, generally monthly under specialist protocols.
Rituximab is generally favored for neuronal surface antibody disease; intracellular antibody-associated disease may require a different approach. Reassess diagnostic accuracy before escalation, especially in antibody-negative presentations.[3]
Safety and Monitoring
Autoimmune encephalitis treatment requires monitoring for infection, metabolic and psychiatric corticosteroid effects, IVIG-associated thrombosis or renal complications, and immunosuppressant toxicity.[3] Before rituximab, screen for hepatitis B infection, obtain a complete blood count, and review vaccination status. Previous hepatitis B infection requires specialist advice about reactivation prevention.[4]
Autoimmune encephalitis requiring prolonged corticosteroids warrants assessment for bone protection and other prophylaxis, including prevention of Pneumocystis jirovecii pneumonia when indicated.[5]
Maintenance and Refractory Disease
Autoimmune encephalitis does not universally require maintenance immunosuppression. Selected patients may receive rituximab, mycophenolate mofetil, or azathioprine according to relapse risk and treatment tolerance. Optimal duration remains uncertain.[5]
Autoimmune encephalitis refractory to appropriate treatment requires specialist reassessment. Tocilizumab and bortezomib have limited supporting evidence and are not routine first-line agents.[3]
Children
Autoimmune encephalitis in children requires pediatric regimens. For N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis, international consensus recommends corticosteroids, with IVIG or plasma exchange in severe disease. Consider rituximab after inadequate improvement approximately two weeks after starting two or more first-line therapies. Maintenance beyond six months is usually unnecessary except with severe, prolonged, or relapsing disease.[6]
Related Management
- Interventions: plasma exchange and procedures for complications.
- Surgery: tumor resection and selected biopsy.
- Symptomatic and supportive therapy: seizures, behavior, autonomic symptoms, and rehabilitation.
- Pediatric considerations.
References
- ↑ 1.0 1.1 Michael BD, Huang Y, McKeever S, et al. Management of suspected infectious and autoimmune encephalitis in adults – National Guidelines from the United Kingdom Joint Societies. J Infect. 2026:106873. doi:10.1016/j.jinf.2026.106873.
- ↑ 2.0 2.1 2.2 Hahn C, Budhram A, Alikhani K, et al. Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults. Can J Neurol Sci. 2024;51(6):734–754. doi:10.1017/cjn.2024.16.
- ↑ 3.0 3.1 3.2 Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021;92(7):757–768. doi:10.1136/jnnp-2020-325300.
- ↑ Genentech. Rituxan (rituximab): prescribing information. DailyMed, United States National Library of Medicine.
- ↑ 5.0 5.1 Abboud H, Probasco J, Irani SR, et al. Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. J Neurol Neurosurg Psychiatry. 2021;92(8):897–907. doi:10.1136/jnnp-2020-325302.
- ↑ Nosadini M, Thomas T, Eyre M, et al. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021;8(5):e1052. doi:10.1212/NXI.0000000000001052.